Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Not Recruiting

Trial ID: NCT01188486

Purpose

The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery. This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.

Official Title

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Stanford Investigator(s)

Billy W Loo, Jr, MD PhD FASTRO FACR
Billy W Loo, Jr, MD PhD FASTRO FACR

Professor of Radiation Oncology (Radiation Therapy)

Heather Wakelee
Heather Wakelee

Winston Chen and Phyllis Huang Professor

Quynh-Thu Le, MD
Quynh-Thu Le, MD

Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)

Joseph Shrager
Joseph Shrager

Professor of Cardiothoracic Surgery

Maximilian Diehn, MD, PhD
Maximilian Diehn, MD, PhD

Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)

Lawrence "Rusty" Hofmann, MD
Lawrence "Rusty" Hofmann, MD

Professor of Radiology (Interventional Radiology)

Ann Leung
Ann Leung

Professor of Radiology (Thoracic Imaging)

Daniel Sze, MD, PhD
Daniel Sze, MD, PhD

Professor of Radiology (Interventional Radiology)

Nishita Kothary, MD
Nishita Kothary, MD

Professor of Radiology (Interventional Radiology)

Eligibility


INCLUSION CRITERIA

   - Either:

      - Established primary lung cancer/ cancer metastatic to lung, OR

      - Lesion suspicious for malignancy in lung, according to the following criteria:

         - Histopathologically confirmed lung cancer or cancer metastatic to lung, OR

         - Plan for biopsy of suspicious lung mass based on imaging (growth on serial
         CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR

         - Known metastatic cancer, with metastases to the lung based on imaging

   - Age > 18 years old

   - Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)

   - No prior surgery, chemotherapy, or radiation for the current lung tumor

EXCLUSION CRITERIA

   - Prior radiotherapy to thorax

   - Iodine allergy

   - Contraindication to receiving radiotherapy, unless undergoing surgery

   - Pregnant

Intervention(s):

drug: Iohexol

radiation: Computed Tomography (CT)

device: Cyberknife

device: Trilogy

device: True Beam

radiation: Stereotactic Body Radiation Therapy (SBRT)

drug: Iodixanol

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.